MktsMarkets

Alto Neuroscience, Inc.
NYSE: ANROKey statistics
ANRO News
Stories mentioning ANRO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 20,294 | 11,996 | 10,525 | 13,124 | 9,974 | 10,800 | 13,060 | 13,184 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 27,138 | 17,055 | 14,951 | 18,682 | 15,676 | 16,997 | 18,886 | 18,341 |
| Operating Income (Loss) | (27,138) | (17,055) | (14,951) | (18,682) | (15,676) | (16,997) | (18,886) | (18,341) |
| Interest Income | 1,561 | 1,561 | 1,532 | 1,683 | 1,827 | 2,135 | 2,500 | 2,658 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | |||||||
| Net Income (Loss) | (26,237) | (16,182) | (14,181) | (17,706) | (15,169) | (15,201) | (16,783) | (16,030) |
| Earnings Per Share (Basic) | (0.80) | (0.56) | (0.52) | (0.65) | (0.56) | (0.62) | (0.62) | (0.60) |
| Earnings Per Share (Diluted) | (0.80) | (0.56) | (0.52) | (0.65) | (0.56) | (0.62) | (0.62) | (0.60) |
| Weighted Average Shares Outstanding (Basic) | 32,893 | 28,852 | 27,104 | 27,072 | 27,049 | 24,602 | 26,959 | 26,913 |
| Weighted Average Shares Outstanding (Diluted) | 32,893 | 28,852 | 27,104 | 27,072 | 27,049 | 24,602 | 26,959 | 26,913 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ANRO
Alto Neuroscience, Inc. (NYSE: ANRO) is a stock listed on the New York Stock Exchange under the ticker symbol ANRO. It last traded at $29.54 (Nov 13, 2026, 4:00 PM ET), down 3.5% on the day. That gives Alto Neuroscience a market capitalisation of $1.2B.
Over the past 52 weeks ANRO has traded between $10.80 and $37.48.
For the quarter ended Mar 31, 2026 it reported a net loss of $26.2M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$26.2M |
| Dec 31, 2025 | — | -$16.2M |
| Sep 30, 2025 | — | -$14.2M |
| Jun 30, 2025 | — | -$17.7M |
From Alto Neuroscience’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…